Research programme: aptamer-based therapeutics - Archemix/GlaxoSmithKline
Latest Information Update: 19 Apr 2011
At a glance
- Originator Archemix Corporation; GlaxoSmithKline
- Developer Archemix Corporation
- Class Oligonucleotides
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 23 Dec 2008 Early research in Inflammation in USA (unspecified route)